B-cell Targeting Therapies in Multiple Sclerosis
A systematic review highlighted B-cell targeting therapies for MS, showing that anti-CD20 monoclonal antibodies (mAbs) are effective but poorly penetrate the CNS and deplete B-cell populations broadly. BTK inhibitors and BAFF-targeting therapies offer new strategies, while CAR-engineered cell therapies can cause significant B-cell depletion, including in the CNS.
- Tags
- #Other
- Most relevant to
- —
Why it matters
Understanding these therapies' limitations and potential can guide future MS treatment strategies, particularly in improving CNS-targeted approaches.
What this does not prove
Current therapies don't effectively control immune responses restricted to the CNS, necessitating improved targeting methods.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not applicable
- Controlled
- Not applicable
- Primary endpoint met
- Not applicable
- Relevant MS type
- All
- Publication date
- 2026-09-24
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceB-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies. ↗DOI: 10.1007/s10072-026-09421-6
Supporting passages (15)
research categoriesB-cell-targeting therapies continue to expand the therapeutic landscape of MS.
study phaseThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
study designThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
randomizedThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
controlledThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
peer reviewedThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
primary endpoint metThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
relevant ms typesB-cell-targeting therapies continue to expand the therapeutic landscape of MS.
publication dateThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
interventionWe discuss established non-cellular approaches, including monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, and B-cell activating factor (BAFF) inhibitors, and examine the rationale, potential advantages, and challenges of emerging chimeric antigen receptor (CAR)-engineered cell therapies.
comparatorThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
primary endpointThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
follow upThis review summarizes the progress and limitations of current and emerging B-cell-targeting strategies for MS.
findingsAnti-CD20 mAbs have demonstrated significant clinical efficacy; however, their limited CNS penetration and broad depletion of B-cell populations highlight the need for more targeted approaches.
limitationsDespite their efficacy in reducing relapse rates and slowing disability accumulation, current B-cell-depleting therapies have important limitations, including incomplete control of compartmentalized immune responses within the central nervous system (CNS).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.